Anti CD5 immunohistochemistry (IHC) antibodies with CE/IVD designation are validated reagents for detecting CD5 antigen in formalin fixed, paraffin embedded (FFPE) tissues. They are essential for accurate lineage assignment and subclassification of lymphoid neoplasms in clinical hematopathology.
Biological Significance of CD5
- Surface glycoprotein: CD5 is a transmembrane protein expressed on mature T lymphocytes and a subset of B 1a cells, modulating T- and B-cell receptor signaling.
- Immune regulation: It attenuates receptor-mediated activation, influencing lymphocyte survival, cytokine production, and immune tolerance.
- Aberrant expression: CD5 expression in B-cell malignancies, outside its normal distribution, is a hallmark of disorders such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
Diagnostic Utility in Hematopathology
- Lineage determination: CD5 IHC differentiates T-cell from B-cell proliferations when morphology is inconclusive.
- B-cell lymphoma subclassification: Aberrant CD5 expression helps identify CLL/SLL and MCL, supporting differential diagnosis among low-grade B-cell lymphomas.
- Prognostic insight: In diffuse large B-cell lymphoma (DLBCL), CD5 positivity marks a distinct subset with potential clinical implications.
Key Features of Anti CD5 CE/IVD Antibodies
- Regulatory validation: CE/IVD designation ensures compliance with in vitro diagnostic standards.
- Optimized performance: Monoclonal clones are validated for FFPE tissues, offering high sensitivity and specificity.
- Integrated diagnostics: CD5 staining should be interpreted alongside tissue morphology, complementary markers, and appropriate controls for reliable hematopathology assessment.
